(Q38247035)

1 September 2017

1 reference

title

Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system (English)

1 reference

1 September 2017

anti-retroviral agent

0 references

1 reference

0 references

1 reference

Andrea Calcagno

1

1 reference

1 September 2017

Giovanni Di Perri

series ordinal

2

1 reference

1 September 2017

Stefano Bonora

series ordinal

3

1 reference

1 September 2017

language of work or name

1 reference

1 October 2014

1 reference

Clinical Pharmacokinetics

1 September 2017

1 reference

1 September 2017

53

1 reference

1 September 2017

10

1 reference

1 September 2017

891-906

1 reference

https://scigraph.springernature.com/pub.10.1007/s40262-014-0171-0

1 September 2017

0 references

cites work

Central nervous system viral invasion and inflammation during acute HIV infection

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Current understanding of HIV-associated neurocognitive disorders pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

HIV Associated Neurocognitive Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

HIV-associated neurocognitive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Cognitive disorders in HIV-infected patients: are they HIV-related?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Monocyte/macrophages and their role in HIV neuropathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Human immunodeficiency virus-restricted replication in astrocytes and the ability of gamma interferon to modulate this restriction are regulated by a downstream effector of the Wnt signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

The Neuropathology of HIV/AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

HIV-1 associated dementia: update on pathological mechanisms and therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Monocyte maturation, HIV susceptibility, and transmigration across the blood brain barrier are critical in HIV neuropathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Infection of human pericytes by HIV-1 disrupts the integrity of the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Effects of antiretroviral treatment on blood-brain barrier integrity and intrathecal immunoglobulin production in neuroasymptomatic HIV-1-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Prevalence and predictors of blood-brain barrier damage in the HAART era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

High levels of divergent HIV-1 quasispecies in patients with neurological opportunistic infections in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Updated research nosology for HIV-associated neurocognitive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Diagnosing symptomatic HIV-associated neurocognitive disorders: self-report versus performance-based assessment of everyday functioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Neurocognitive function in HIV infected patients on antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

HIV and neurocognitive dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Human immunodeficiency virus type 1 RNA Levels in different regions of human brain: quantification using real-time reverse transcriptase-polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Pharmacokinetics of lamivudine and BCH-189 in plasma and cerebrospinal fluid of nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

PK/PD assessment in CNS drug discovery: Prediction of CSF concentration in rodents for P-glycoprotein substrates and application to in vivo potency estimation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Utility of CSF in translational neuroscience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

CSF penetration by antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Antiretroviral drugs and the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Recently infiltrating MAC387(+) monocytes/macrophages a third macrophage population involved in SIV and HIV encephalitic lesion formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Age-associated dysregulation of microglial activation is coupled with enhanced blood-brain barrier permeability and pathology in APP/PS1 mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Incidence and clinical features of cerebrovascular disease among HIV-infected adults in the Southeastern United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

HIV stroke risk: evidence and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Predicting intestinal absorption of raltegravir using a population-based ADME simulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Spectrum of cerebrospinal fluid findings in various stages of human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Blood-brain barrier abnormalities in the acquired immunodeficiency syndrome: immunohistochemical localization of serum proteins in postmortem brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Increased blood-brain barrier permeability in neuro-asymptomatic HIV-1-infected individuals--correlation with cerebrospinal fluid HIV-1 RNA and neopterin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Blood-brain barrier damage and brain penetration of antiepileptic drugs: role of serum proteins and brain edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Raltegravir cerebrospinal fluid concentrations in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

The brain entry of HIV-1 protease inhibitors is facilitated when used in combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Increasing extracellular protein concentration reduces intracellular antiretroviral drug concentration and antiviral effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Protein-free efavirenz concentrations in cerebrospinal fluid and blood plasma are equivalent: applying the law of mass action to predict protein-free drug concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Etravirine in CSF is highly protein bound

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

The multidrug transporter P-glycoprotein in pharmacoresistance to antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Inhibition of P-glycoprotein activity at the primate blood-brain barrier increases the distribution of nelfinavir into the brain but not into the cerebrospinal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Intestinal transporters: enhanced absorption through P-glycoprotein-related drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Impact of pharmacogenetics on CNS side effects related to efavirenz.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Low atazanavir concentrations in cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Maraviroc-containing regimen suppresses HIV replication in the cerebrospinal fluid of patients with neurological symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Zidovudine in patients with human immunodeficiency virus (HIV) infection and Kaposi sarcoma. A phase II randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Zidovudine reduces intrathecal immunoactivation in patients with early human immunodeficiency virus type 1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Factors in AIDS dementia complex trial design: results and lessons from the abacavir trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Study on didanosine concentrations in cerebrospinal fluid. Implications for the treatment and prevention of AIDS dementia complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

A single-dose study to assess the penetration of stavudine into human cerebrospinal fluid in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Stavudine entry into cerebrospinal fluid after single and multiple doses in patients infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Making the most of sparse clinical data by using a predictive-model-based analysis, illustrated with a stavudine pharmacokinetic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

The distribution of the anti-HIV drug, tenofovir (PMPA), into the brain, CSF and choroid plexuses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Stable concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid during 2 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Lopinavir cerebrospinal fluid steady-state trough concentrations in HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Antiretroviral drug treatment of CNS HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Therapy failure following selection of enfuvirtide-resistant HIV-1 in cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. The HIV Neurobehavioral Research Center Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Role of neuroimaging in HIV-associated neurocognitive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Increased microglia activation in neurologically asymptomatic HIV-infected patients receiving effective ART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Improved neurocognitive test performance in both arms of the SMART study: impact of practice effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Acute Meningoencephalitis in Chronic Human Immunodeficiency Virus (HIV) Infection: Putative Central Nervous System Escape of HIV Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Reversible dementia in a patient with central nervous system escape of human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

HIV encephalitis despite suppressed viraemia: a case of compartmentalized viral escape.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

CSF viral escape in a patient with HIV-associated neurocognitive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

The effect on human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavir-based antiretroviral therapy vs. lopinavir/ritonavir monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Protease inhibitor monotherapy and the CNS: peace of mind?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

The role of compartment penetration in PI-Monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

The cerebrospinal fluid HIV risk score for assessing central nervous system activity in persons with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study a5199, the International Neurological Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Cognitive function after several years of antiretroviral therapy with stable central nervous system penetration score

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Central nervous system antiretroviral penetration and cognitive functioning in largely pretreated HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Peripheral blood HIV DNA is associated with atrophy of cerebellar and subcortical gray matter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

HIV DNA reservoir increases risk for cognitive disorders in cART-naïve patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Presence of HIV-1 R5 viruses in cerebrospinal fluid even in patients harboring R5X4/X4 viruses in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Alterations in cerebrospinal fluid chemokines are associated with maraviroc exposure and in vivo metabolites measurable by magnetic resonance spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Antiretroviral neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Antiretroviral drugs induce oxidative stress and neuronal damage in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Cerebrovascular disease in HIV-infected individuals in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Mechanisms of ischemic stroke in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

HIV protease inhibitor exposure predicts cerebral small vessel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Antiretroviral medications disrupt microglial phagocytosis of β-amyloid and increase its production by neurons: implications for HIV-associated neurocognitive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Discordance Between Cerebral Spinal Fluid and Plasma HIV Replication in Patients with Neurological Symptoms Who Are Receiving Suppressive Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Lopinavir with Ritonavir Reduces the HIV RNA Level in Cerebrospinal Fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0171-0

Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study

21 January 2018

1 reference

12 December 2020

Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment

1 reference

12 December 2020

Plasma and cerebrospinal fluid saquinavir concentrations in patients receiving combination antiretroviral therapy

1 reference

12 December 2020

Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.

1 reference

12 December 2020

Effect of zidovudine on cerebrospinal fluid in patients with HIV infection and acute neurological disease

1 reference

12 December 2020

2',3'-Dideoxycytidine alters calcium buffering in cultured dorsal root ganglion neurons

1 reference

12 December 2020

Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin

1 reference

12 December 2020

HIV-1 RNA detectable with ultrasensitive quantitative polymerase chain reaction in plasma but not in cerebrospinal fluid during combination treatment with zidovudine, lamivudine and indinavir

1 reference

12 December 2020

Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group

1 reference

12 December 2020

Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting

1 reference

12 December 2020

Low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy

1 reference

12 December 2020

Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition

1 reference

12 December 2020

Distributed model analysis of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine distribution in brain tissue and cerebrospinal fluid.

1 reference

12 December 2020

Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011

1 reference

12 December 2020

Effect of nucleoside analogs on neurite regeneration and mitochondrial DNA synthesis in PC-12 cells

1 reference

12 December 2020

Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics

1 reference

12 December 2020

Effects of zidovudine in 30 patients with mild to end-stage AIDS dementia complex.

1 reference

12 December 2020

Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control

1 reference

12 December 2020

Virological Response in Cerebrospinal Fluid to Antiretroviral Therapy in a Large Italian Cohort of HIV-Infected Patients with Neurological Disorders

1 reference

12 December 2020

Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV

1 reference

12 December 2020

Viral response in stable patients switching to fosamprenavir/ritonavir monotherapy (the FONT Study)

1 reference

12 December 2020

10.1007/S40262-014-0171-0

Identifiers

DOI

1 reference

Dimensions Publication ID

1 September 2017

0 references

1 reference